Introduction: Who Should Undergo Diagnostics

Chronic lymphocytic leukaemia is often discovered unexpectedly during routine medical examinations, even before you notice any signs of illness. In fact, more than half of people with CLL first learn about their condition through a standard blood test performed as part of a regular health check-up^[1][2]. Because the disease can progress slowly, it may take months or even years before symptoms appear that prompt you to seek medical attention.

You should consider seeking medical evaluation if you notice certain warning signs in your body. These include painless swelling of lymph nodes in your neck, underarm, stomach, or groin area. Other concerning symptoms include persistent weakness or feeling unusually tired, fever and frequent infections, easy bruising or bleeding, and unexplained weight loss^[2][4]. Night sweats that drench your clothing and bedding are another symptom that warrants medical attention. You might also experience pain or a sense of fullness below your ribs, which can happen when CLL affects your liver or spleen^[1].

For people who have already been diagnosed with CLL and have undergone treatment, regular diagnostic monitoring remains essential throughout your life. CLL typically cannot be completely cured, meaning the disease may return after periods of remission^[5][10]. Remission means there are no signs of active leukaemia in your body, but small numbers of cancer cells may still remain. Because of this, your healthcare team will want to check your blood regularly to catch any changes early.

People who have close relatives with CLL should discuss their family history with their doctor. Studies show that individuals with a biological parent, sibling, or child who has CLL are two to four times more likely to develop the condition themselves^[4]. While this doesn’t mean you’ll definitely get CLL, it does suggest that regular health monitoring may be particularly valuable for you.

Diagnostic Methods for Initial CLL Detection

The journey to diagnosing chronic lymphocytic leukaemia typically begins with blood tests that examine the cells flowing through your bloodstream. When doctors suspect CLL, they order several specific tests to confirm the diagnosis and understand the characteristics of your disease. These tests help distinguish CLL from other types of blood cancers and guide decisions about treatment.

The first test is usually a complete blood count, which measures the number of different cells in a blood sample. In CLL, this test reveals an unusually high number of lymphocytes, a type of white blood cell^[2][14]. For a CLL diagnosis, lymphocyte counts in the blood are typically greater than or equal to 5,000 cells per cubic millimeter^[15]. The complete blood count also checks your red blood cells and platelets, which can be reduced in CLL because the abnormal cells crowd out healthy blood cells in your bone marrow.

A peripheral blood smear is another important diagnostic tool. During this test, a healthcare professional examines a drop of your blood under a microscope to see what the cells actually look like. In chronic lymphocytic leukaemia, the smear may show many small, round lymphocytes that appear similar to healthy cells but behave differently^[14]. Sometimes these cells appear as “smudge cells,” which are fragile lymphocytes that break apart during the preparation of the blood sample^[3].

Understanding the specific proteins on the surface of cancer cells is crucial for confirming a CLL diagnosis. This testing, called flow cytometry and immunophenotyping, identifies markers that distinguish CLL cells from other types of lymphoma or leukaemia cells^[15][8]. CLL cells have a characteristic pattern: they are positive for CD5, CD19, CD20, and CD23 markers and display either kappa or lambda light chains on their surface^[8]. These markers act like identification tags that help doctors accurately diagnose your condition.

Genetic testing plays an increasingly important role in CLL diagnosis because certain DNA changes affect how the disease behaves and responds to treatment. Your doctors will likely order fluorescence in situ hybridization, known as FISH, which looks for specific chromosome changes in your leukaemia cells^[15]. This test searches for deletions in chromosomes 11, 13, and 17, as well as an extra copy of chromosome 12 and a translocation between chromosomes 11 and 14. Each of these changes provides information about how aggressive your CLL might be.

Testing for changes in the TP53 gene is particularly important because mutations in this gene can affect how well certain treatments work^[15][11]. The TP53 gene normally helps control cell growth and prevents cancer development. When it’s mutated or deleted, CLL cells may not respond as well to standard chemotherapy treatments. Similarly, doctors test for changes in the IGH gene to better understand your disease characteristics.

During your initial evaluation, your doctor will also perform a physical examination to check for swollen lymph nodes in your neck, underarms, and groin, as well as to feel for an enlarged spleen or liver^[15][14]. They will measure the largest palpable lymph nodes to establish a baseline for future comparisons. This physical assessment, combined with blood tests, usually provides enough information to diagnose CLL without needing more invasive procedures.

In most cases, a bone marrow biopsy is not required to diagnose CLL^[14][15]. However, your healthcare provider may recommend this test if your blood counts are unusually low without a clear explanation, or if they need additional information about how the disease is affecting your bone marrow. During a bone marrow biopsy, a doctor removes a small sample of bone marrow tissue, usually from your hip bone, to examine the cells more closely.

Additional laboratory tests help assess how CLL might be affecting your overall health. Your doctor will check your serum immunoglobulin levels because CLL can reduce the production of antibodies that fight infection^[15]. Low immunoglobulin levels explain why people with CLL have an increased risk of infections. Blood chemistry panels measure your kidney and liver function, including tests for creatinine, bilirubin, and liver enzymes. Your doctor may also measure lactate dehydrogenase and beta-2-microglobulin, which can provide information about disease activity.

If you have symptoms suggesting immune complications, your doctor may order specialized tests. An antiglobulin test, also called a direct Coombs test, checks for autoimmune hemolytic anemia, a condition where your immune system attacks your own red blood cells^[15]. This complication can occur in people with CLL and requires specific treatment approaches. Testing for cold agglutinins, reticulocyte count, indirect bilirubin, and serum haptoglobin helps evaluate this possibility.

Imaging tests are not routinely required for CLL diagnosis but may be recommended in specific situations. Computed tomography (CT) scans are typically only ordered if you have significant swelling of lymph nodes on physical examination, prompting doctors to check for enlarged lymph nodes deeper inside your abdomen or chest^[15][14]. These scans can help determine the extent of the disease but are not needed for everyone with CLL.

Diagnostics for Recurrent CLL and Clinical Trial Qualification

When chronic lymphocytic leukaemia returns after a period of remission, this is called relapsed or recurrent CLL. Some people experience their first relapse years after initial treatment, while others may have multiple relapses over time^[5][10]. During the course of CLL, you might have several relapses, though the leukaemia often comes back slowly, meaning you may not need further treatment immediately. Understanding whether and when your CLL has returned requires careful diagnostic evaluation.

A relapsed patient is defined as someone who previously achieved complete or partial remission but shows evidence of disease progression after six months or more^[12]. Complete remission means cancer is no longer detectable when tested, though a few CLL cells may still remain in your body. Partial remission is usually defined as a measurable cancer reduction of at least 50 percent. The relapse may occur after a long period of complete remission following initial treatment, or it might happen within months after achieving only a partial response to second-line or third-line therapy.

When doctors evaluate you for possible recurrent CLL, they repeat many of the same tests used for initial diagnosis. This includes a complete blood count with differential to check your lymphocyte levels and other blood cells, as well as chemistry panels to assess kidney and liver function^[15]. Your doctor will measure lactate dehydrogenase and beta-2-microglobulin again because rising levels of these markers can indicate increasing disease activity.

Retesting for genetic changes is a critical step when evaluating recurrent CLL. Your doctors will repeat fluorescence in situ hybridization (FISH) testing to check for chromosomal deletions and other abnormalities^[5][10]. More importantly, they will test again for TP53 gene mutations because these genetic changes can occur during the course of your disease even if they weren’t present at diagnosis. When TP53 mutations are found, certain targeted therapies work better than traditional chemotherapy^[11].

The presence or absence of a deletion in the short arm of chromosome 17, called del(17p), significantly impacts treatment decisions for relapsed CLL. If you have relapsed or refractory CLL with del(17p) or TP53 mutation, treatment typically involves targeted therapy drugs such as ibrutinib, acalabrutinib, zanubrutinib, or venetoclax rather than chemotherapy^[11]. These genetic tests help your doctor predict which medications are most likely to control your disease.

When considering clinical trial participation, researchers require specific diagnostic tests to determine if you qualify for the study. Most clinical trials for CLL include detailed eligibility criteria based on blood counts, genetic markers, and previous treatments. Trials may require flow cytometry and immunophenotyping to confirm that you have CLL rather than another lymphoproliferative disorder. They often specify particular TP53 mutation status or other genetic features as either inclusion or exclusion criteria.

Clinical trials typically require documentation of your previous treatments and their outcomes. This includes records showing what treatments you received, how long you were in remission, and why treatment was restarted. Researchers need to know whether your CLL is truly relapsed (meaning it responded initially but then returned) or refractory (meaning it never responded well to treatment). This distinction helps ensure that trial participants have similar disease characteristics, which makes the study results more reliable.

Performance status assessment is another important component of clinical trial qualification. Researchers use standardized scales like the Eastern Cooperative Oncology Group (ECOG) performance status to measure how well you can perform daily activities^[12]. This assessment considers whether you are fully active, have restricted strenuous activities but can do light work, are capable of self-care but unable to work, or require more significant assistance. Many clinical trials only accept patients with good performance status because they are more likely to tolerate experimental treatments.

Before enrolling in clinical trials, you may need imaging studies to establish a baseline measurement of lymph node size and organ involvement. CT scans of your chest, abdomen, and pelvis help researchers document the extent of disease and provide a comparison point for measuring treatment response. Some trials require specific imaging at defined intervals to determine if the experimental therapy is working.

Bone marrow aspiration and biopsy may be required for certain clinical trials, particularly those studying new drugs that target cells in the bone marrow or those measuring very precise treatment responses^[14]. During these procedures, doctors remove samples of liquid bone marrow and solid bone marrow tissue to examine the percentage of CLL cells and their characteristics. While not always necessary for standard care of recurrent CLL, these tests provide detailed information that helps researchers evaluate new treatments.

Testing for infectious diseases is standard before starting many clinical trials. Your doctors will check your blood for hepatitis B, hepatitis C, and HIV because these infections can complicate cancer treatment and affect your immune system^[15]. Some trials exclude patients with certain infections, while others include them but monitor more closely. These tests protect your safety and help researchers understand any complications that arise during the study.

Some clinical trials focus on specific subgroups of CLL patients based on how long they remained in remission after previous treatment. For example, a trial might specifically enroll people whose CLL relapsed within two years of finishing chemotherapy, or it might target those who achieved at least a three-year remission. These criteria require careful documentation of your treatment timeline and response, which your healthcare team compiles from your medical records.

Laboratory tests measuring organ function are essential for clinical trial screening because they ensure you can safely receive experimental treatments. Kidney function tests, including serum creatinine and calculated glomerular filtration rate, show how well your kidneys can filter waste from your blood. Liver function tests, including bilirubin, transaminases, and alkaline phosphatase, indicate whether your liver can process medications effectively^[15]. Abnormal results in these tests might exclude you from certain trials or require dose adjustments of study medications.